Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $4.31 in the prior trading day, Evolent Health Inc (NYSE: EVH) closed at $4.2, down -2.55%. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 1.95 million shares were traded. EVH stock price reached its highest trading level at $4.4011 during the session, while it also had its lowest trading level at $4.18.
Ratios:
Our goal is to gain a better understanding of EVH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.33. In the meantime, Its Debt-to-Equity ratio is 1.29 whereas as Long-Term Debt/Eq ratio is at 1.26.
On November 13, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $7.
On January 10, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on January 10, 2025, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’25 when Springstubb Brendan B bought 10,000 shares for $3.82 per share. The transaction valued at 38,199 led to the insider holds 58,821 shares of the business.
Holder Diane bought 2,735 shares of EVH for $25,518 on Mar 06 ’25. The Director now owns 70,584 shares after completing the transaction at $9.33 per share. On Mar 06 ’25, another insider, McCarthy Daniel Joseph, who serves as the PRESIDENT of the company, bought 11,040 shares for $9.01 each. As a result, the insider paid 99,470 and bolstered with 389,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 487078752 and an Enterprise Value of 1434388608. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.23 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at 0.698 whereas that against EBITDA is 17.967.
Stock Price History:
The Beta on a monthly basis for EVH is 0.31, which has changed by -0.6749226 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $13.61, while it has fallen to a 52-week low of $3.49. The 50-Day Moving Average of the stock is -38.61%, while the 200-Day Moving Average is calculated to be -52.57%.
Shares Statistics:
The stock has traded on average 3.61M shares per day over the past 3-months and 5795590 shares per day over the last 10 days, according to various share statistics. A total of 111.59M shares are outstanding, with a floating share count of 102.96M. Insiders hold about 7.74% of the company’s shares, while institutions hold 117.99% stake in the company. Shares short for EVH as of 1763078400 were 18762717 with a Short Ratio of 5.20, compared to 1760486400 on 17620752. Therefore, it implies a Short% of Shares Outstanding of 18762717 and a Short% of Float of 17.03.
Earnings Estimates
. The current rating of Evolent Health Inc (EVH) reflects the combined expertise of 12.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.05, with high estimates of $0.17 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.13 and -$0.03 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is $0.3, with 9.0 analysts recommending between $0.78 and -$0.09.
Revenue Estimates
15 analysts predict $470.22M in revenue for. The current quarter. It ranges from a high estimate of $484.1M to a low estimate of $464.2M. As of. The current estimate, Evolent Health Inc’s year-ago sales were $646.54MFor the next quarter, 15 analysts are estimating revenue of $552.2M. There is a high estimate of $608.14M for the next quarter, whereas the lowest estimate is $510.91M.
A total of 14 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $1.89B, while the lowest revenue estimate was $1.87B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $2.55BBased on 11 analysts’ estimates, the company’s revenue will be $2.44B in the next fiscal year. The high estimate is $2.52B and the low estimate is $2.3B.
